Document Detail


Polymyositis-dermatomyositis:25 years of follow-up of 50 patients disease course, treatment, prognostic factors.
MedLine Citation:
PMID:  2132429     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Therapeutic results were analysed in 50 patients, including 17 with polymyositis (PM) and 30 with dermatomyositis (DM). All patients were treated with prednisone (Encorton, Polfa) and 47% of patients with PM and 73% with DM required combined treatment with prednisone and cytostatic agents, mostly with cyclophosphamide (Endoxan G.D.R.). Long-term treatment monitored with the clinical status led to remissions persisting after treatment discontinuation in 17.6% of PM patients and 24.2% of DM patients. In 64.7% of PM patients and 57.6% of DM patients regression of the clinical signs of the disease was achieved but these patients required further treatment. No information was obtained on 5 cases. Four DM patients died. The cumulative 17-year survival rate of PM patients was 100%, and that of DM patients was 78.8% . In 45 follow-up cases, the mortality was 8.9%. Side effects of the combined treatment included most frequently mucosal candidiasis (22.2%), transient leucopenia (14.8%) and recurrent respiratory tract infections (11.1%). In 5 cases liver biopsy was done and histological examination disclosed moderate fatty, glycogen and vacuolar degeneration of the hepatocytes. The statistical analysis of prognostic factors such as the diagnosis of PM or DM, sex, age at disease onset, disease duration till diagnosis establishing and beginning of treatment, fever, dysphagia, circulatory and respiratory changes, leucocytosis nad ESR at the beginning of the disease showed that sex (female), older age at disease onset and respiratory system changes may be accepted as poor prognosis factors.
Authors:
H Chwalińska-Sadowska; H Małdykowa
Related Documents :
7962969 - Factors responsible for death in patients with pemphigus.
12451369 - Primary follicular mucinosis: long-term follow-up of patients younger than 40 years wit...
17522949 - The role of malignancies in patients with catastrophic anti-phospholipid (asherson's) s...
19573169 - Long-term results of patients with malignant carcinoid syndrome receiving octreotide lar.
1761349 - Spleen cell dialyzable extracts (scde) mediated immunotherapy for patients with myasthe...
17878679 - Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in...
20517769 - Risk factors for complex regional pain syndrome in patients with traumatic extremity in...
11513099 - Route learning performance in alzheimer disease patients.
18416969 - Serum inflammatory protein profiles in patients with chronic rhinosinusitis undergoing ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Materia medica Polona. Polish journal of medicine and pharmacy     Volume:  22     ISSN:  0025-5246     ISO Abbreviation:  Mater Med Pol     Publication Date:    1990 Jul-Sep
Date Detail:
Created Date:  1992-01-14     Completed Date:  1992-01-14     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0236526     Medline TA:  Mater Med Pol     Country:  POLAND    
Other Details:
Languages:  eng     Pagination:  213-8     Citation Subset:  IM    
Affiliation:
Department of Connective Tissue Diseases, Institute of Rheumatology, Warszawa, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cyclophosphamide / therapeutic use
Dermatomyositis / drug therapy*,  mortality
Female
Follow-Up Studies
Humans
Male
Middle Aged
Myositis / drug therapy*,  mortality
Prednisone / therapeutic use*
Prognosis
Chemical
Reg. No./Substance:
50-18-0/Cyclophosphamide; 53-03-2/Prednisone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polymyositis-dermatomyositis--a 25-year follow-up of 50 patients (analysis of clinical symptoms and ...
Next Document:  Natural history of peptic ulcer disease in Poland. Part X. Peptic ulcer disease and urinary tract di...